The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global aerosol delivery devices market was valued at US$ 44.4 Billion in 2022.
We expect the global aerosol delivery devices market to exhibit a CAGR of 5.4% during 2023-2028.
The rising prevalence of chronic respiratory infections, along with the increasing demand for aerosol delivery devices for treating obstructive airway diseases in healthcare settings, is primarily driving the global aerosol delivery devices market.
The sudden outbreak of the COVID-19 pandemic has led to the rising demand for aerosol delivery devices at home and across numerous healthcare institutions for treating the coronavirus infected patients suffering with acute respiratory infections.
Based on the product, the global aerosol delivery devices market has been segmented into dry powder inhalers, metered dose inhalers, nebulizers. Among these, metered dose inhalers currently hold the majority of the total market share.
Based on the distribution channel, the global aerosol delivery devices market can be divided into retail pharmacies, hospital pharmacies, and online stores. Currently, retail pharmacies exhibit a clear dominance in the market.
On a regional level, the market has been classified into North America, Asia-Pacific, Europe, Latin America, and Middle East and Africa, where North America currently dominates the global market.
Some of the major players in the global aerosol delivery devices market include 3M Company, Aerogen, GlaxoSmithKline plc, Johnson & Johnson, Koninklijke Philips N.V., Merck & Co. Inc., Metall Zug AG, Recipharm AB (publ), Teva Pharmaceutical Industries Ltd., and Vectura Group plc.
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at